P
Philip C. Calder
Researcher at University of Southampton
Publications - 808
Citations - 70822
Philip C. Calder is an academic researcher from University of Southampton. The author has contributed to research in topics: Polyunsaturated fatty acid & Eicosapentaenoic acid. The author has an hindex of 125, co-authored 747 publications receiving 59110 citations. Previous affiliations of Philip C. Calder include Southampton General Hospital & Radboud University Nijmegen Medical Centre.
Papers
More filters
Book ChapterDOI
Introduction to fatty acids and lipids
TL;DR: The purpose of this article is to describe the structure, function and metabolism of fatty acids and lipids that are of particular importance in the context of parenteral nutrition.
Journal ArticleDOI
Expert Opinion on Benefits of Long-Chain Omega-3 Fatty Acids (DHA and EPA) in Aging and Clinical Nutrition.
Barbara Troesch,Manfred Eggersdorfer,Alessandro Laviano,Yves Rolland,A. David Smith,Ines Warnke,Arved Weimann,Philip C. Calder +7 more
TL;DR: An expert group reviewed the data on omega-3 LCPUFAs in specific patient populations and medical conditions and found evidence for benefits in cognitive health, age- and disease-related decline in muscle mass, cancer treatment, surgical patients and critical illness.
Journal ArticleDOI
Is Palmitoleic Acid a Plausible Nonpharmacological Strategy to Prevent or Control Chronic Metabolic and Inflammatory Disorders
TL;DR: The immune-metabolic effects of palmitolesic acid observed in cell culture, animal models, and humans are described to answer the question of whether palmitoleic acid is a plausible nonpharmacological strategy to prevent, control, or ameliorate chronic metabolic and inflammatory disorders.
Journal ArticleDOI
Gut microbiota and osteoarthritis management: An expert consensus of the European society for clinical and economic aspects of osteoporosis, osteoarthritis and musculoskeletal diseases (ESCEO).
Emmanuel Biver,Francis Berenbaum,Ana M. Valdes,Islene Araujo de Carvalho,Laure B. Bindels,Maria Luisa Brandi,Philip C. Calder,Vincenzo Castronovo,Etienne Cavalier,Antonio Cherubini,Cyrus Cooper,Elaine M. Dennison,Claudio Franceschi,Nicholas R Fuggle,Andrea Laslop,Pierre Miossec,Thierry Thomas,Şansın Tüzün,Nicola Veronese,Mila Vlaskovska,Jean-Yves Reginster,René Rizzoli +21 more
TL;DR: An expert working group was convened by the European Society for Clinical and Economic Aspects of Osteoporosis, Osteoarthritis and Musculoskeletal Diseases to review the potential contribution of GMB to OA, and it is found that GMB is a critical determinant of drug metabolism and bioavailability and may influence the response of OA medications.